Abstract
Bevacizumab (Avastin, Genetech/Roche) is an anti-angiogenic drug approved for treating patients with malignant gliomas that reduces edema and mass effect, but has been suggested to promote multifocal tumor spread within the brain. Patients with systemic malignancies are also treated with bevacizumab, but there is limited information regarding effects of the drug on the neuroimaging or neuropathological features of metastatic CNS disease. We report 2 patients with non-small cell lung carcinomas who had received bevacizumab for their systemic cancers and then developed cognitive deficits consistent with white matter dementia. Diagnosis of leptomeningeal carcinomatosis (LC) was confounded and delayed by the finding of atypical neuroimaging features, including minimal to absent leptomeningeal enhancement and unusual perivascular and punctate hemorrhagic lesions and multifocal subgyral signal abnormalities suspicious for vasculitis or small vessel vasculopathy. Neuropathological assessment confirmed LC but, in the autopsy case also disclosed extraordinary perivascular spread of individual metastatic tumor cells to the depth of capillaries. The pattern was reminiscent of vascular “cooption” by tumor seen in experimental animals in preclinical trials of bevacizumab. Small infarctions were associated with perivascular tumor and vasculopathy, unusual features of LC in patients who do not receive bevacizumab. In the biopsied patient, multiple perivascular tumor nodules were identified in superficial cortex. In these two patients, bevacizumab appeared to alter neuroimaging characteristics of LC, confounded diagnosis and possibly also influenced the pattern of tumor spread of LC. More cases will need to be studied to confirm this latter finding.
Similar content being viewed by others
References
Yan L, Hsu K, Beckman RA (2008) Antibody-based therapy for solid tumors. Cancer J 14:178–183
Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614–625
Simonds J, Miller F, Mandel J, Davidson TM (2009) The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119:988–992
Torcuator R, Zuniga R, Mohan Y, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol. doi: 10.1007/s11060-009-9801-z
Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152–1160
Dietrich J, Norden AD, Wen PY (2008) Emerging antiangiogenic treatments for gliomas—efficacy and safety issues. Curr Opin Neurol 21:736–744
Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2008) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2008.10.043
Chamberlain MC, Johnston S (2009) Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115:1734–1743
Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217–1222
Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729
Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314
Kokmen E, Naessens JM, Offord KP (1987) A short test of mental status: description and preliminary results. Mayo Clin Proc 62:281–288
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Dubois R, Scacheysky A, Lityan I, Pillon B (2000) The FAB: A fronal assessment battery at bedside. Neurology 55:1621–1628
Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A (2008) High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 10:700–708
Mathews MS, Linskey ME, Hasso AN, Fruehauf JP (2008) The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol 70:649–652
Yachnis AT (2005) Vascular disease. In: Prayson RA (ed) Neuropathology. Elsevier Churchill Livingstone, Philadelphia, PA, pp 46–49 2005
Olson ME, Chernik NL, Posner JB (1974) Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30:122–137
Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772
Kastenbauer S, Wiesmann M, Pfister H-W (2000) Cerebral vasculopathy and multiple infarctions in a woman with carcinomatous meningitis while on treatment with intrathecal methotrexate. J Neurooncol 48:41–45
Guttman DH, Cantor CR, Piacente GJ, McCluskey LF (1990) Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis. J Neurooncol 9:183–185
Klein P, Haley EC, Wooten GF, VandenBerg SR (1989) Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol 46:1149–1152
Solans-Laque R, Bosch-Gil JA, Perez-Bocanegra C, Selva-O’Callaghan A, Simeon-Aznar CP, Vilardell-Tarres M (2008) Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 35:294–304
Taccone FS, Salmon I, Marechal R, Blecic SA (2007) Paraneoplastic vasculitis of central nervous system presenting as recurrent cryptogenic stroke. Int J Clin Oncol 12:155–159
Geisler JP, Schraith DF, Manahan KJ, Sorosky JI (2004) Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer. Gynecol Oncol 92:705–707
Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Y (2002) Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study. Br J Cancer 87:1360–1364
Birlik M, Akar S, Tuzel E, Onen F, Ozer E, Manisali M, Kirkali Z, Akkoc N (2004) Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder. J Cancer Res Clin Oncol 130:122–125
Voorburg AM, van Beek FT, Slee PH, Seldenrijk CA, Schramel FM (2002) Vasculitis due to gemcitabine. Lung Cancer 36:203–205
Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980–982
Levy CF, Oo KZ, Fireman F, Pierre L, Bania MA, Sadanandan S, Yamashiro DJ, Bender JL (2008) Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer 52:669–671 2009
Acknowledgments
The authors thank Ms. Lisa Litzenberger for expert photographic assistance, Mrs. Diane Hutchinson for manuscript preparation, and Dr. Zachary Weber who performed the general autopsy. This study was supported, in part, by funding from the Plachy-Rubin Fund for Neuro-oncology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kleinschmidt-DeMasters, B.K., Damek, D.M. The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 96, 375–384 (2010). https://doi.org/10.1007/s11060-009-9969-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-009-9969-2